Viromed Medical AG plans to acquire all shares in ActivCell Group AG by way of a capital increase against contribution in kind with exclusion of subscription rights Pinneberg, 17 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in ActivCell Group AG, Switzerland, and thus s [ … ]

Viromed Medical AG: Successful start of trading on XETRA   Listing on leading German financial market increases liquidity and expands investor base Aiming to expand its pioneering role in the medical use of cold plasma technology Pinneberg, 2 September 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has reached another mil [ … ]

Viromed Medical AG: Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect Pinneberg, 5 July 2024 – Viromed Medical GmbH, a wholly owned subsidiary of Viromed Medical AG, and terraplasma medical GmbH have today terminated their business relation with immediate effect. As part of the previous cooperation [ … ]

  Hamburg / Munich - 06.10.2023 - For people with chronic and non-healing wounds, there is a solution: cold atmospheric plasma (KAP). As proven by a pilot study commissioned by Munich-based terraplasma medical GmbH, a company of the Hamburg-based Viromed Group, the innovative wound and skin treatment of the cold plasma technique is superior to stan [ … ]